Azathioprine: State of the Art in Inflammatory Bowel Disease

REFERENCES

• Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 1994;35:360–2.
   PubMed Web of Science ®Google Scholar
• Personal communication R. England, Glaxo Wellcome, Middlesex, UK.
   Google Scholar
• Van Os EC, Zins BJ, Sandborn WJ, Mays DC, Tremaine WJ, Mahoney DW, et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 1996;39:63–8.
   PubMed Web of Science ®Google Scholar
• Arndt CAS, Balis FM, McCully CL, Jeffries SL, Doherty K, Murphy R, et al. Bioavailability of low-dose vs high-dose 6-mercaptopurine. Clin Pharmacol Ther 1988;43:588–91.
   PubMed Web of Science ®Google Scholar
• Chan GLC, Erdman GR, Gruber SA, Matas AJ, Canafax DM. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 1990;30: 358–63.
   Google Scholar
• Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics; monogenic inheritance of erythrocyte thiopurine methyl-transferase activity. Am J Hum Genet 1980;32:651–62.
   PubMed Web of Science ®Google Scholar
• Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225–9.
   PubMed Web of Science ®Google Scholar
• Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercapto-purine: a long-term, randomized, double-blind study. N Engl J Med 1980;302:981–7.
   PubMed Web of Science ®Google Scholar
• Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn’s disease. A meta-analysis. Ann Intern Med 1995;123:132–42.
   PubMed Web of Science ®Google Scholar
• Rhodes J, Bainton D, Beck P, Cambell H. Controlled trial of azathioprine in Crohn’s disease. Lancet 1971(7737);2: 1273–6.
   Google Scholar
• Klein M, Binder HJ, Mitchell M, Aaronson R, Spiro H. Treatment of Crohn’s disease with azathioprine: a controlled evaluation. Gastroenterology 1974;66:916–22.
   Google Scholar
• Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995;37:674–8.
   PubMed Web of Science ®Google Scholar
• Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern Jr F, et al. National Cooperative Crohn’s Disease Study: Results of drug treatment. Gastroenterology 1979;77:847–69.
   Google Scholar
• Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn’s disease. Gastroenterology 1993;105:367–72.
   PubMed Web of Science ®Google Scholar
• Willoughby JMT, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn’s disease. Lancet 1971;2(731): 944–7.
   PubMed Web of Science ®Google Scholar
• O’Donoghue DP, Dawson AM, Powell-Tuck J, Bown RL, Lennard-Jones J. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn’s disease. Lancet 1978;2 (8097):955–7.
   Google Scholar
• Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn’s disease. Am J Dig Dis 1975;20:721–6.
   PubMedGoogle Scholar
• Bouhnik Y, Lemann M, Mary J-Y, Scemama G, Taï R, Matuchansky C, et al. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 1996;347: 215–9.
   Google Scholar
• Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on a controlled therapeutic trial. Br Med J 1974;4:627–30.
   PubMed Web of Science ®Google Scholar
• Hawthorne AB, Logan RFA, Hawkey CJ, Foster PN, Axon ATR, Swarbrick ET, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 1992;305: 20–2.
   PubMed Web of Science ®Google Scholar
• Caprilli R, Carratu R, Babbini M. A double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis. Preliminary report. Am J Dig Dis 1975;20:115–20.
   Google Scholar
• Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975;69:96–9.
   Google Scholar
• Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J Clin Res Ed 1982;284:1291–2.
   PubMed Web of Science ®Google Scholar
• George J, Present DH, Pou R, Bodian C, Rubin PH. The longterm outcome of ulcerative colitis treated with 6-mercapto-purine. Am J Gastroenterol 1996;91: 1711–4.
   Google Scholar
• Haber CJ, Meltzer SJ, Present DH, Korelitz BI. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 1986;91: 982–6.
   PubMed Web of Science ®Google Scholar
• Present DH, Meltzer SJ, Krumholtz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111:641–9.
   Google Scholar
• Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34: 1081–5.
   Google Scholar
• Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343: 1249–51.
   Google Scholar
• Alstead EM, Ritchie JK, Lennard-Jones JE, Farthing MJG, Clark ML. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990;99:443–6.
   Google Scholar
• Francella A, Dayan A, Rubin P, Chapman M, Present D. 6-Mercaptopurine (6-MP) is safe therapy for child bearing patients with inflammatory bowel disease (IBD), a case controlled study [Abstract]. Gastroenterology 1996;110:A909.
   Google Scholar
• Sandborn WJ, Van Os EC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn’s disease. Gastroenterology 1995;109:1808–17.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn’s disease. Gastroenterology 1997;112: 1475–81.
   Google Scholar
• Zins BJ, Sandborn WJ, McKinney JA, Mays DC, Van Os EC, Tremaine WJ, et al. A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. J Clin Pharmacol 1997;37:38–46.
   PubMed Web of Science ®Google Scholar
• Kurowski V, Iven H. Plasma concentrations and organ distribution of thiopurines after oral application of azathioprine in mice. Cancer Chemother Pharmacol 1991;28:7–14.
   PubMed Web of Science ®Google Scholar
• Gruber SA, Hrushesky WJM, Cipolle RJ, Erdmann GR, Burke BA, Skjei KL, et al. Local immunosuppression with reduced systemic toxicity in a canine renal allograft model. Trans-plantation 1989;48:936–43.
   Google Scholar
• Gruber SA, Canafax DM, Erdmann GR, Cipolle RJ, Burke BA, Rabatin JT, et al. The pharmacokinetic advantage of local 6-mercaptopurine infusion in a canine renal transplant model. Transplantation 1989;48:928–35.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996;91: 423–33.
   PubMed Web of Science ®Google Scholar